

Revision date: 17-Apr-2015 Version: 2.0 Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Nicergoline Powder and Solvent for Oral Solution

Trade Name: Sermion 10 mg/ml Powder and Solvent for Oral Solution

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as cognition activator

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017

1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd

Ramsgate Road Sandwich, Kent CT13 9NJ

United Kingdom +00 44 (0)1304 616161

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

Australian Hazard Classification

(NOHSC):

No data available

Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Material Name: Nicergoline Powder and Solvent for Oral Page 2 of 7

Solution

Revision date: 17-Apr-2015 Version: 2.0

3. COMPOSITION / INFORMATION ON INGREDIENTS								
Ingredient	CAS Number	EU	EU Classification	GHS	%			
		EINECS/ELINCS		Classification				
		List						
Nicergoline	27848-84-6	248-694-6	Xn;R22	Acute Tox.4 (H302)	20-40			

Ingredient	CAS Number	EU	EU Classification	GHS	%
		EINECS/ELINCS		Classification	
		List			
Methylparaben	99-76-3	202-785-7	Not Listed	Not Listed	*
Water	7732-18-5	231-791-2	Not Listed	Not Listed	*

Additional Information: * Proprietary

> Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this

mixture has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of First Aid Measures

If irritation occurs or persists, get medical attention. Flush eyes with water as a precaution Eye Contact:

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of

For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information. Exposure:

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Emits toxic fumes of carbon monoxide, carbon dioxide, oxides of nitrogen and bromine-

Products: containing compounds

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Material Name: Nicergoline Powder and Solvent for Oral Page 3 of 7

Solution

Revision date: 17-Apr-2015 Version: 2.0

6. ACCIDENTAL RELEASE MEASURES

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:

Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Additional Consideration for

Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store at room temperature in properly labeled containers. Keep away from heat, sparks and

flames.

Specific end use(s): Pharmaceutical product used as cognition activator

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL), The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Nicergoline

Pfizer Occupational Exposure OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³)

Band (OEB):

Exposure Controls

Engineering controls should be used as the primary means to control exposures. General **Engineering Controls:**

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Personal Protective Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE). **Equipment:**

Hands: Not required for the normal use of this product. Impervious gloves are recommended if skin

contact with drug product is possible and for bulk processing operations.

Not required for the normal use of this product. Wear safety glasses or goggles if eye contact Eyes:

is possible.

Skin: Not required for the normal use of this product. Impervious protective clothing is

recommended if skin contact with drug product is possible and for bulk processing operations.

Material Name: Nicergoline Powder and Solvent for Oral Page 4 of 7

Solution

Revision date: 17-Apr-2015 Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Respiratory protection: None required under normal conditions of use. If airborne exposures are within or exceed the

Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection

factor sufficient to control exposures to the bottom of the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder / Liquid Color: No data available /

Colorless

Odor: No data available. Odor Threshold: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

Solvent Solubility:
Water Solubility:
PH:
No data available
Partition Coefficient: (Method, pH, Endpoint, Value)

Tartaric acid
No data available
Nicergoline
No data available
Methylparaben
No data available

Water

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

No data available

Flammablity:

Autoignition Temperature (Solid) (°C):No data availableFlammability (Solids):No data availableFlash Point (Liquid) (°C):No data availableUpper Explosive Limits (Liquid) (% by Vol.):No data availableLower Explosive Limits (Liquid) (% by Vol.):No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

Products:

Material Name: Nicergoline Powder and Solvent for Oral Page 5 of 7

Solution

Revision date: 17-Apr-2015 Version: 2.0

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual

ingredients

Short Term: May be harmful if swallowed. May cause drowsiness, insomnia, nervousness, and dizziness.

Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including

Ingestion of this material may cause effects similar to those seen in clinical use including hypotension (low blood pressure), dizziness, headache and drowsiness. Adverse effects associated with therapeutic use include skin rash and gastrointestinal disturbances.

Acute Toxicity: (Species, Route, End Point, Dose)

Nicergoline

Rat Oral LD 50 1193 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Nicergoline

Embryo / Fetal Development Rat Oral Not teratogenic

Embryo / Fetal Development Rabbit Fetotoxicity

Embryo / Fetal Development Rat Intramuscular Not Teratogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

Material Name: Nicergoline Powder and Solvent for Oral Page 6 of 7

Solution

Revision date: 17-Apr-2015 Version: 2.0

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Nicergoline

CERCLA/SARA 313 Emission reporting

California Proposition 65

Not Listed

Not Listed

Standard for the Uniform Scheduling

Schedule 4

for Drugs and Poisons:

EU EINECS/ELINCS List 248-694-6

Methylparaben

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Eisted

Not

Water

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Not Listed

Not Listed

Not Listed

Not Listed

Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Material Name: Nicergoline Powder and Solvent for Oral Page 7 of 7

Solution

Revision date: 17-Apr-2015 Version: 2.0

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed

Xn - Harmful

R22 - Harmful if swallowed.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on

Ingredients. Updated Section 16 - Other Information.

Revision date: 17-Apr-2015

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet